TY - CHAP
T1 - Peptide receptor radionuclide therapy for neuroendocrine Tumors in Germany
T2 - First results of a multi-institutional cancer registry
AU - Hörsch, Dieter
AU - Ezziddin, Samer
AU - Haug, Alexander
AU - Gratz, Klaus Friedrich
AU - Dunkelmann, Simone
AU - Krause, Bernd Joachim
AU - Schümichen, Carl
AU - Bengel, Frank M.
AU - Knapp, Wolfram H.
AU - Bartenstein, Peter
AU - Biersack, Hans Jürgen
AU - Plöckinger, Ursula
AU - Schwartz-Fuchs, Sabine
AU - Baum, R. P.
N1 - Funding Information:
We are indebted to all patients who agreed to be registered. The registry of peptide receptor radionuclide therapy was founded in 2009 by U. Plöckinger and S. Schwartz-Fuchs with great enthusiasm. Data collection and analysis were performed by S. Skrobek-Engel and H. Franz of Lohmann and Birkner in Berlin, Germany. Supported by Covidien Inc., ITG, MDS Nordion, and Eckert and Ziegler Radiopharma GmbH.
PY - 2013
Y1 - 2013
N2 - Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor-expressing neuroendocrine tumors. However, published data result mainly from retrospective monocentric studies. We initiated a multi-institutional, prospective, board-reviewed registry for patients treated with peptide receptor radionuclide therapy in Germany in 2009. In five centers, 297 patients were registered. Primary tumors were mainly derived from pancreas (117/297) and small intestine (80/297), whereas 56 were of unknown primary. Most tumors were well differentiated with median Ki67 proliferation rate of 5% (range 0.9-70%). Peptide receptor radionuclide therapy was performed using mainly yttrium-90 and/or lutetium-177 as radionuclides in 1-8 cycles. Mean overall survival was estimated at 213 months with follow-up between 1 and 230 months after initial diagnosis, and 87 months with follow-up between 1 and 92 months after start of peptide receptor radionuclide therapy. Median overall survival was not yet reached. Subgroup analysis demonstrated that best results were obtained in neuroendocrine tumors with proliferation rate below 20%. Our results indicate that peptide receptor radionuclide therapy is an effective treatment for well- and moderately differentiated neuroendocrine tumors irrespective of previous therapies and should be regarded as one of the primary treatment options for patients with somatostatin receptor-expressing neuroendocrine tumors.
AB - Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor-expressing neuroendocrine tumors. However, published data result mainly from retrospective monocentric studies. We initiated a multi-institutional, prospective, board-reviewed registry for patients treated with peptide receptor radionuclide therapy in Germany in 2009. In five centers, 297 patients were registered. Primary tumors were mainly derived from pancreas (117/297) and small intestine (80/297), whereas 56 were of unknown primary. Most tumors were well differentiated with median Ki67 proliferation rate of 5% (range 0.9-70%). Peptide receptor radionuclide therapy was performed using mainly yttrium-90 and/or lutetium-177 as radionuclides in 1-8 cycles. Mean overall survival was estimated at 213 months with follow-up between 1 and 230 months after initial diagnosis, and 87 months with follow-up between 1 and 92 months after start of peptide receptor radionuclide therapy. Median overall survival was not yet reached. Subgroup analysis demonstrated that best results were obtained in neuroendocrine tumors with proliferation rate below 20%. Our results indicate that peptide receptor radionuclide therapy is an effective treatment for well- and moderately differentiated neuroendocrine tumors irrespective of previous therapies and should be regarded as one of the primary treatment options for patients with somatostatin receptor-expressing neuroendocrine tumors.
UR - http://www.scopus.com/inward/record.url?scp=84867093346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867093346&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-27994-2_25
DO - 10.1007/978-3-642-27994-2_25
M3 - Chapter
C2 - 22918775
AN - SCOPUS:84867093346
SN - 9783642279935
T3 - Recent Results in Cancer Research
SP - 457
EP - 465
BT - Theranostics, Gallium-68, and Other Radionuclides
PB - Springer Science and Business Media, LLC
ER -